Update on pharmacotherapy for ocular surface squamous neoplasia  

作　　者：Ghada Al Bayyat Dan Arreaza-Kaufman Nandini Venkateswaran Anat Galor Carol L.Karp 

机构地区：[1]Bascom Palmer Eye Institute,University of Miami,900 NW 17th Street,Miami,FL 33136,USA [2]Miami Veterans Hospital,Miami,FL 33125,USA

出　　处：《Eye and Vision》2019年第1期201-212,共12页眼视光学杂志（英文）

基　　金：Supported by the Department of Veterans Affairs,Veterans Health Administration,Office of Research and Development,Clinical Sciences Research EPID-006-15S(Dr.Galor);R01EY026174(Dr.Galor);NIH Center Core Grant P30EY014801;Research to Prevent Blindness,Unrestricted Grant(Dr.Galor);the Ronald and Alicia Lepke Grant,the Lee and Claire Hager Grant,the Elaine and Robert Baer Grant;the H.Scott Huizenga Grant;the Emilyn Page and Mark Feldberg Grant,the Jose Ferreira de Melo Grant;the Michele and Ted Kaplan Grant;the Kathy and Richard Lesser Grant;the Azar Family Grant(institutional grants).

摘　　要：The most frequently encountered non-pigmented tumor of the ocular surface is ocular surface squamous neoplasia(OSSN).Over the past two decades,the pharmacological management of OSSN has grown,with topical 5-fluorouracil,mitomycin,and interferon alpha 2b all being successfully used to treat this disease.Other agents,such as anti-vascular endothelial growth factor(VEGF),retinoic acid,cidofovir and Aloe vera,have less frequently been used in the treatment of OSSN.This review will discuss these pharmacologic agents,summarizing available data and presenting the approach to the treatment of these tumors.

关 键 词：Ocular surface squamous neoplasia(OSSN) MITOMYCIN-C Interferon alpha 2b 5-FLUOROURACIL Conjunctival neoplasia Corneal neoplasia 

分 类 号：R73[医药卫生—肿瘤]